The present disclosure relates to formulations of Inecalcitol a 14-EPI-Analogue of Vitamin D, and long chain triglycerides (LCT) chosen among olive oil, sunflower oil, and their mixtures. The disclosed formulations are characterized by an improved absorption profile over the Medium Chain Triglycerides (MCT) formulation of inecalcitol. Conditions which may be treated with the formulations include: rickets, osteoporosis, osteomalacia, psoriasis, autoimmune diseases such as multiple sclerosis or type I diabetes, hyperparathyroidism, benign prostate hyperplasia, any type of cancer or any vitamin D associated disease.
